API | atacicept

atacicept Report issue

Biologics Recombinant protein Experimental

AACT ChEMBL MeSH

Active Ingredient History

NOW

Atacicept is a recombinant fusion protein designed to inhibit B cells, thereby suppressing autoimmune disease. The designer protein combines the binding site for two cytokines that regulate maturation, function, and survival of B cells - B-lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL), with the constant region of immunoglobin. Atacicept blocks activation of B cells by the tumor necrosis factor receptor superfamily member 13B, a transmembrane receptor protein found predominantly on the surface of B cells. Like the monoclonal antibody belimumab, atacicept blocks the binding of BLyS, but it also blocks APRIL. Binding of these TACI ligands induces proliferation, activation, and longevity of B cells and thus their production of autoantibodies. Atacicept is thought to selectively impair mature B cells and plasma cells with less impact on progenitor cells and memory B cells. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
atacicept

More Chemistry

Pharmacology

Mechanisms of Action:
- Tumor necrosis factor ligand superfamily member 13 (Homo sapiens) ^UniProt
- Tumor necrosis factor ligand superfamily member 13B (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

atacicept | taci-fc5 | taci-ig | taci receptor-igg fc fragment fusion protein

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)

Arthritis, Rheumatoid (Phase 2)

Glomerulonephritis, IGA (Phase 2)

Lupus Erythematosus, Systemic (Phase 2/Phase 3)

Lupus Nephritis (Phase 2/Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Optic Neuritis (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 15
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue